Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

Date Documents

Recent SEC Filings

Filing date Form Description Filing Group Downloads
4

Statement of changes in beneficial ownership of securities

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports
4

Statement of changes in beneficial ownership of securities

3,4,5
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
8-K

Report of unscheduled material events or corporate event

Current Reports

Fact Sheets

There are currently no items available.

Recent Press Releases

Date Title and Summary
Toggle Summary Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $45.8 Million for April 2022
– EXPAREL average daily sales for April 2022 were 109 percent of April 2021 – TAMPA, Fla., May 12, 2022 (GLOBE NEWSWIRE) --  Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary
Toggle Summary Pacira BioSciences to Present at Two Healthcare Conferences in May
TAMPA, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2022 RBC Capital Markets Global Healthcare Conference in New York, on Tuesday, May 17 th at
Toggle Summary Pacira BioSciences Reports First Quarter 2022 Financial Results
-- First quarter revenue of $158 million, up 33% over prior year -- -- Strong topline performance delivers net income and significantly positive adjusted EBITDA -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., May 04, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.
Toggle Summary Pacira to Report First Quarter 2022 Financial Results on Wednesday May 4, 2022
TAMPA, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Wednesday, May 4, 2022. Following the release, the company will host a live conference call and
Toggle Summary Pacira BioSciences Reports Preliminary Revenues of $157.4 to $158.4 Million for the First Quarter of 2022
EXPAREL achieved record net product sales of $51.2 million for month of March with average daily sales at 116% of the prior year TAMPA, Fla., April 12, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and
Toggle Summary Pacira BioSciences to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 21 st Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Tuesday, April 12, 2022.
Toggle Summary Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $42.6 Million for February 2022
– EXPAREL average daily sales for February 2022 were 117% of February 2021 – TAMPA, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary
Toggle Summary Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference
TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 10:15 AM ET on Wednesday, March 16, 2022 in Miami.
Toggle Summary Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results
— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patients have received EXPAREL since launch — — Conference call today at 8:30 a.m.
Toggle Summary Pacira to Report 2021 Financial Results on Thursday February 24, 2022
TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before the open of the U.S. markets on Thursday, February 24, 2022.